Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feiyang Liu

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
European Journal of Medicinal Chemistry|March 16, 2018
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemiaQiang Wang, Feiyang Liu, Shuang Qi, et al.
Cancer Letters|January 27, 2019
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical modelsTingting Lu, Cheng Chen, Aoli Wang, et al.
ACS Chemical Biology|April 19, 2013
Discovery of a selective irreversible BMX inhibitor for prostate cancerFeiyang Liu, Xin Zhang, Ellen Weisberg, et al.
European Journal of Medicinal Chemistry|September 26, 2018
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitorBeilei Wang, Jiaxin Wu, Yun Wu, et al.
Therapeutic Advances in Medical Oncology|June 18, 2019
Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumorsFeiyang Liu, Fengming Zou, Cheng Chen, et al.
Journal of Medicinal Chemistry|August 23, 2016
Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT KinaseBinhua Li, Aoli Wang, Juan Liu, et al.
Oncotarget|April 14, 2016
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AMLAoli Wang, Hong Wu, Cheng Chen, et al.
Oncotarget|June 21, 2016
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)Feiyang Liu, Beilei Wang, Qiang Wang, et al.
Oncotarget|April 16, 2016
Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignancesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Oncotarget|July 23, 2016
Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignanciesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
European Journal of Medicinal Chemistry|March 16, 2018
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemiaQiang Wang, Feiyang Liu, Shuang Qi, et al.
Cancer Letters|January 27, 2019
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical modelsTingting Lu, Cheng Chen, Aoli Wang, et al.
ACS Chemical Biology|April 19, 2013
Discovery of a selective irreversible BMX inhibitor for prostate cancerFeiyang Liu, Xin Zhang, Ellen Weisberg, et al.
European Journal of Medicinal Chemistry|September 26, 2018
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitorBeilei Wang, Jiaxin Wu, Yun Wu, et al.
Therapeutic Advances in Medical Oncology|June 18, 2019
Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumorsFeiyang Liu, Fengming Zou, Cheng Chen, et al.
Journal of Medicinal Chemistry|August 23, 2016
Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT KinaseBinhua Li, Aoli Wang, Juan Liu, et al.
Oncotarget|April 14, 2016
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AMLAoli Wang, Hong Wu, Cheng Chen, et al.
Oncotarget|June 21, 2016
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)Feiyang Liu, Beilei Wang, Qiang Wang, et al.
Oncotarget|April 16, 2016
Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignancesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Oncotarget|July 23, 2016
Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignanciesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Pageof 9